NZ606366A - Stabilization of fsh - Google Patents

Stabilization of fsh

Info

Publication number
NZ606366A
NZ606366A NZ606366A NZ60636611A NZ606366A NZ 606366 A NZ606366 A NZ 606366A NZ 606366 A NZ606366 A NZ 606366A NZ 60636611 A NZ60636611 A NZ 60636611A NZ 606366 A NZ606366 A NZ 606366A
Authority
NZ
New Zealand
Prior art keywords
salts
fsh
pharmaceutically acceptable
formulation
stabilization
Prior art date
Application number
NZ606366A
Other languages
English (en)
Inventor
Helen Ulrika Sjögren
Heidi Louise Bagger
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ606366(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to NZ628962A priority Critical patent/NZ628962A/en
Publication of NZ606366A publication Critical patent/NZ606366A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
NZ606366A 2010-07-30 2011-07-28 Stabilization of fsh NZ606366A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ628962A NZ628962A (en) 2010-07-30 2011-07-28 Stabilisation of fsh

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Publications (1)

Publication Number Publication Date
NZ606366A true NZ606366A (en) 2014-08-29

Family

ID=43216624

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ628962A NZ628962A (en) 2010-07-30 2011-07-28 Stabilisation of fsh
NZ606366A NZ606366A (en) 2010-07-30 2011-07-28 Stabilization of fsh

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ628962A NZ628962A (en) 2010-07-30 2011-07-28 Stabilisation of fsh

Country Status (27)

Country Link
US (3) US8993732B2 (zh)
EP (3) EP2417982A1 (zh)
JP (3) JP5860047B2 (zh)
KR (2) KR101991756B1 (zh)
CN (2) CN103052398B (zh)
AR (1) AR082776A1 (zh)
AU (1) AU2011284702C1 (zh)
BR (1) BR112013002312B1 (zh)
CA (1) CA2805864A1 (zh)
DK (1) DK2598160T3 (zh)
ES (1) ES2623634T3 (zh)
HR (1) HRP20170386T1 (zh)
HU (1) HUE033592T2 (zh)
IL (2) IL223821A (zh)
JO (1) JO3229B1 (zh)
LT (1) LT2598160T (zh)
MX (2) MX341464B (zh)
NZ (2) NZ628962A (zh)
PL (1) PL2598160T3 (zh)
PT (1) PT2598160T (zh)
RS (1) RS55772B1 (zh)
RU (1) RU2574012C2 (zh)
SA (1) SA114350786B1 (zh)
SI (1) SI2598160T1 (zh)
TW (1) TWI439283B (zh)
WO (1) WO2012013742A2 (zh)
ZA (1) ZA201209497B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
EP3068374A1 (en) * 2013-11-12 2016-09-21 Cadila Healthcare Limited Formulation for gonadotropins
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN111727049A (zh) 2017-12-07 2020-09-29 阿道恰公司 Ph 7的包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的可注射溶液
JP2021505605A (ja) 2017-12-07 2021-02-18 アドシア ５．８〜８．５のｐＩを有する少なくとも１つの基礎インスリン、および、カルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むｐＨ７を有する注射溶液
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU607001A1 (ru) * 1976-01-14 1978-05-15 Краснодарский Государственный Научно-Исследовательский И Проектный Институт Нефтяной Промышленности Способ получени кислотного раствора
DE69524456T2 (de) 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
EP1618896A3 (en) * 1996-05-29 2010-07-14 DelSiTech Oy Dissolvable oxides for biological applications
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
BR9912243A (pt) * 1998-07-23 2001-10-16 Lilly Co Eli Formulações de fsh e variantes de fsh, produtos e processos
DK1740213T3 (da) * 2004-04-07 2012-04-10 Ares Trading Sa Væskeformulering til væksthormoner
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
WO2011099036A2 (en) 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Also Published As

Publication number Publication date
RS55772B1 (sr) 2017-07-31
BR112013002312A2 (pt) 2018-03-20
LT2598160T (lt) 2017-04-10
ES2623634T3 (es) 2017-07-11
HRP20170386T1 (hr) 2017-05-05
EP2598160A2 (en) 2013-06-05
RU2012157154A (ru) 2014-09-10
HUE033592T2 (hu) 2017-12-28
JP2016102127A (ja) 2016-06-02
RU2574012C2 (ru) 2016-01-27
PT2598160T (pt) 2017-03-30
JP2018048188A (ja) 2018-03-29
WO2012013742A2 (en) 2012-02-02
EP3144010A1 (en) 2017-03-22
IL223821A (en) 2017-01-31
CN103052398B (zh) 2015-09-16
JP6522711B2 (ja) 2019-05-29
MX2013000681A (es) 2013-02-27
KR20180008916A (ko) 2018-01-24
SI2598160T1 (sl) 2017-07-31
DK2598160T3 (en) 2017-03-27
PL2598160T3 (pl) 2017-06-30
US20150265681A1 (en) 2015-09-24
CN105106939A (zh) 2015-12-02
JO3229B1 (ar) 2018-03-08
KR101991756B1 (ko) 2019-06-21
IL249920A0 (en) 2017-03-30
ZA201209497B (en) 2013-08-28
US8993732B2 (en) 2015-03-31
US9463221B2 (en) 2016-10-11
KR20130143692A (ko) 2013-12-31
AR082776A1 (es) 2013-01-09
TWI439283B (zh) 2014-06-01
JP2013532677A (ja) 2013-08-19
MX341464B (es) 2016-08-22
WO2012013742A3 (en) 2012-04-19
CA2805864A1 (en) 2012-02-02
CN103052398A (zh) 2013-04-17
SA114350786B1 (ar) 2015-07-09
AU2011284702B2 (en) 2015-05-14
JP5860047B2 (ja) 2016-02-16
MX356951B (es) 2018-06-21
AU2011284702C1 (en) 2015-09-03
AU2011284702A1 (en) 2013-02-07
US20130210727A1 (en) 2013-08-15
US20170216405A1 (en) 2017-08-03
TW201208694A (en) 2012-03-01
KR101820115B1 (ko) 2018-01-18
EP2598160B1 (en) 2017-02-22
EP2417982A1 (en) 2012-02-15
BR112013002312B1 (pt) 2021-09-21
NZ628962A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
NZ606366A (en) Stabilization of fsh
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
PH12014502040A1 (en) Heterocyclyl compounds
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
IN2015DN01156A (zh)
MX348823B (es) Formulaciones estables de linaclotida.
AU2012214029A8 (en) Rorgammat inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2016014927A3 (en) Crystalline form of nicotinamide riboside
MX2013005407A (es) 5-halopirazolcarboxamidas.
SG10201804817TA (en) Delayed release compositions of linaclotide
PH12014502805A1 (en) Novel indanesulfamide derivative
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX2012001876A (es) Composicion de sal.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
NZ605860A (en) Use of vitamin c, and chromium-free vitamin k or 2-methyl-1,4-naphthalendione, and compositions thereof for treating a polycystic disease
PH12015500611A1 (en) Oral care composition
WO2014083580A3 (en) Pharmaceutical compositions of regadenoson
MY155829A (en) Pyrazole derivatives, preparation thereof and therapeutic use thereof
WO2012173382A3 (ko) 탄시논ⅱａ를 유효성분으로 함유하는 피부 외용제 조성물
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
WO2019125166A3 (en) Hyaluronic acid formulations
IN2013MU02612A (zh)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2016 BY CPA GLOBAL

Effective date: 20150612

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2017 BY CPA GLOBAL

Effective date: 20160617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2018 BY CPA GLOBAL

Effective date: 20170615

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2019 BY JAMES + WELLS

Effective date: 20180719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2020 BY IPAN GMBH

Effective date: 20190718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2021 BY IPAN GMBH

Effective date: 20200714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2022 BY IPAN GMBH

Effective date: 20210714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2023 BY IPAN GMBH

Effective date: 20220714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2024 BY IPAN GMBH

Effective date: 20230714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2025 BY IPAN GMBH

Effective date: 20240715